BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32659948)

  • 21. TERT promoter mutations in thyroid cancer.
    Liu R; Xing M
    Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
    Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
    Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter mutations and long-term survival in patients with thyroid cancer.
    Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
    Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
    Insilla AC; Proietti A; Borrelli N; Macerola E; Niccoli C; Vitti P; Miccoli P; Basolo F
    Oncol Lett; 2018 Mar; 15(3):2763-2770. PubMed ID: 29435002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral heterogeneity and
    Juratli TA; Thiede C; Koerner MVA; Tummala SS; Daubner D; Shankar GM; Williams EA; Martinez-Lage M; Soucek S; Robel K; Penson T; Krause M; Appold S; Meinhardt M; Pinzer T; Miller JJ; Krex D; Ely HA; Silverman IM; Christiansen J; Schackert G; Wakimoto H; Kirsch M; Brastianos PK; Cahill DP
    Oncotarget; 2017 Dec; 8(65):109228-109237. PubMed ID: 29312603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors.
    Umbricht CB; Conrad GT; Clark DP; Westra WH; Smith DC; Zahurak M; Saji M; Smallridge RC; Goodman S; Zeiger MA
    Clin Cancer Res; 2004 Sep; 10(17):5762-8. PubMed ID: 15355904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
    Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TERTmonitor-qPCR Detection of
    Brás JP; Jesus TT; Prazeres H; Lima J; Soares P; Vinagre J
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hürthle cell tumor of the thyroid gland. Analysis of a series of 33 cases].
    Janser JC; Pusel J; Rodier JF; Navarrete E; Rodier D
    J Chir (Paris); 1989 Nov; 126(11):619-24. PubMed ID: 2685000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
    Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of TERT promoter mutations in human cancers.
    Vinagre J; Almeida A; Pópulo H; Batista R; Lyra J; Pinto V; Coelho R; Celestino R; Prazeres H; Lima L; Melo M; da Rocha AG; Preto A; Castro P; Castro L; Pardal F; Lopes JM; Santos LL; Reis RM; Cameselle-Teijeiro J; Sobrinho-Simões M; Lima J; Máximo V; Soares P
    Nat Commun; 2013; 4():2185. PubMed ID: 23887589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
    Lade-Keller J; Yuusufi S; Riber-Hansen R; Steiniche T; Stougaard M
    Melanoma Res; 2018 Oct; 28(5):398-409. PubMed ID: 29570169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter mutations in solitary fibrous tumour.
    Demicco EG; Wani K; Ingram D; Wagner M; Maki RG; Rizzo A; Meeker A; Lazar AJ; Wang WL
    Histopathology; 2018 Nov; 73(5):843-851. PubMed ID: 29985536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
    Ge J; Liu MY; Li L; Deng Q; Liu F; Luo Y; Wang L; Yao G; Zhu D; Lu H; Liang M; Deng S; Zhou R; Luo T
    Int J Clin Exp Pathol; 2020; 13(2):230-238. PubMed ID: 32211103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.